• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Devex CheckUp

    Devex Checkup: The secrets of South Africa’s COVID-19 vaccine deals

    In this week's edition: details of South Africa's COVID-19 vaccine deals released, Ugandan activists want donors to review programs after anti-gay bill, and END Fund's new board chair brings local approach in efforts to end NTDs.

    By Andrew Green // 07 September 2023

    The South African government did not get a fair deal on its COVID-19 vaccines and now everyone knows it.

    The details of the government’s contracts with drug companies were publicly released this week, and among the most outrageous findings was that manufacturers such as Johnson & Johnson charged South Africa more for vaccines than they did wealthier countries in Europe. Although J&J says their final price was $7.50 per dose, which is lower than what they charged the EU.

    At the same time, some manufacturers prevented the South African government from donating their doses to other countries without permission. Some of the contracts also included broad indemnification clauses that pushed the liability onto the government if any complications arose.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in
    • Democracy, Human Rights & Governance
    • Global Health
    • Trade & Policy
    • Funding
    • The END Fund
    • Health Justice Initiative
    • South Africa
    • Uganda
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Andrew Green

      Andrew Green@_andrew_green

      Andrew Green, a 2025 Alicia Patterson Fellow, works as a contributing reporter for Devex from Berlin.

    Search for articles

    Related Jobs

    • Research, Policy & Advocacy Coordinator (Hybrid)
      Melbourne, Australia | Australia | East Asia and Pacific
    • Compensation Specialist
      Devex Talent Solutions
      Argentina | Bolivia | Chile | Colombia | Ecuador | Paraguay | Uruguay | Latin America and Caribbean
    • Chief Migration Health Officer and Head of Sub-Office
      Ho Chi Minh City, Viet Nam | Viet Nam | East Asia and Pacific
    • See more

    Most Read

    • 1
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 2
      How AI-powered citizen science can be a catalyst for the SDGs
    • 3
      Opinion: The missing piece in inclusive education
    • 4
      How to support climate-resilient aquaculture in the Pacific and beyond
    • 5
      Opinion: India’s bold leadership in turning the tide for TB

    Trending

    Financing for Development Conference

    The Trump Effect

    Newsletters

    Related Stories

    Devex CheckUpDevex CheckUp: Why isn’t there enough cholera vaccine to go around?

    Devex CheckUp: Why isn’t there enough cholera vaccine to go around?

    Devex CheckUpDevex CheckUp: Exempted or not? Trump’s orders spark confusion

    Devex CheckUp: Exempted or not? Trump’s orders spark confusion

    Devex CheckUpDevex CheckUp: The Trump administration puts Gavi support on the chopping block

    Devex CheckUp: The Trump administration puts Gavi support on the chopping block

    Devex CheckUpDevex CheckUp: WHO's emergencies czar is out — here's who's in

    Devex CheckUp: WHO's emergencies czar is out — here's who's in

    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement